Three Papers Examining The Experience, Value Frameworks And Value-Based Purchasing Of Novel Drugs
Loading...
Links to Files
Permanent Link
Author/Creator
Author/Creator ORCID
Date
2022-01-01
Type of Work
Department
School of Public Policy
Program
Public Policy
Citation of Original Publication
Rights
Distribution Rights granted to UMBC by the author with a 1 year embargo. Access will begin on Dec. 1, 2023.
This item may be protected under Title 17 of the U.S. Copyright Law. It is made available by UMBC for non-commercial research and education. For permission to publish or reproduce, please see http://aok.lib.umbc.edu/specoll/repro.php or contact Special Collections at speccoll(at)umbc.edu
This item may be protected under Title 17 of the U.S. Copyright Law. It is made available by UMBC for non-commercial research and education. For permission to publish or reproduce, please see http://aok.lib.umbc.edu/specoll/repro.php or contact Special Collections at speccoll(at)umbc.edu
Subjects
Abstract
This dissertations explores real-world experience, value assessment frameworks, and value-based purchasing arrangements for novel medications. The first paper is a systematic literature review of outcomes of these novel therapies, where I show that the real-world experience with these medications�with never-before-seen mechanisms of action or those that address unmet medical needs for serious conditions�have high costs and do not often align with the outcomes reported in clinical trials. The need to increase access to these novel therapies is often hindered by questions about the cost and value these innovative medications. Advocates of value-based purchasing promote it as a potential solution to concerns that drug prices are increasingly misaligned with their therapeutic benefits. However, defining drug value is not easy. The second paper explores seven value-assessment frameworks developed by U.S-based organizations. These frameworks vary by the elements of a medication's value taken into account, how elements are measured and valued, how elements are combined into an overall assessment of a medicine's value and how that could then be linked to the reimbursement price. In response to increasing costs of these novel medications, state Medicaid programs have experimented with a variety of models for value-based purchasing arrangements (VBAs) to contain spending and achieve value in prescription drugs. The third paper is from in-depth, semi-structured, qualitative interviews conducted with representatives from four state Medicaid programs that are currently implementing VBAs with drug manufacturers. While interest in Medicaid VBAs grows and states experience some success, there are challenges with the negotiation process, selecting and monitoring patient outcomes, and concerns with high launch prices persist.